Poly(ADP-ribose) polymerase (PARP) inhibitors, which exploit synthetic lethality in ATM-deficient cells, have demonstrated efficacy in treating solid tumors with ATMaberrations, such as prostate and breast cancer (Fong et al. 2009). The gene discussed is ATM; the disease is breast carcinoma.